Trevi Therapeutics, Inc.
TRVI · Nasdaq · United States
Share price · TRVI
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TRVI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Nov 2026-8.1%
Nothing announced by TRVI that day or the session before.
- 6 Nov 2026+11.9%
Nothing announced by TRVI that day or the session before.
- 27 Oct 2026+6.7%
Nothing announced by TRVI that day or the session before.
- 20 Oct 2026+7.8%
Nothing announced by TRVI that day or the session before.
- 20 Jul 2026-12.1%
Nothing announced by TRVI that day or the session before.
- 17 Jul 2026+9.9%
Nothing announced by TRVI that day or the session before.
- 14 Jul 2026+8.4%
Nothing announced by TRVI that day or the session before.
- 13 Jul 2026-7.4%
Nothing announced by TRVI that day or the session before.
- 7 Jul 2026+8.6%
Nothing announced by TRVI that day or the session before.
- 16 Jun 2026+5.0%
Nothing announced by TRVI that day or the session before.
Share of unusual movement by asset
For each asset, the share of TRVI's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Nalbuphine ER(Haduvio) | Phase 3 | Kappa-opioid receptor (agonist); mu-opioid receptor (antagonist)Small molecule | Prurigo NodularisIdiopathic Pulmonary Fibrosis Chronic Cough in Idiopathic Pulmonary Fibrosis |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $19M | $28M+ $272M short-term inv. | $21M-$20M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $15M | $54M+ $265M short-term inv. | $18M-$17M operating cash flow | report ↗ |
| 2026-Q1 | — | $9.9M | $19M+ $152M short-term inv. | $13M-$17M operating cash flow | report ↗ |
| 2025-Q3 | — | $10M | $57M+ $138M short-term inv. | $12M-$11M operating cash flow | report ↗ |
| 2025-Q2 | — | $9.4M | $117M+ $87M short-term inv. | $12M-$10M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.8M | $19M+ $84M short-term inv. | $10M-$13M operating cash flow | report ↗ |
| 2024-Q3 | — | $11M | $16M+ $49M short-term inv. | $13M-$9.6M operating cash flow | report ↗ |
| 2024-Q2 | — | $10M | $13M+ $57M short-term inv. | $12M-$8.7M operating cash flow | report ↗ |
| 2024-Q1 | — | $8.8M | $14M+ $59M short-term inv. | $11M-$10M operating cash flow | report ↗ |
| 2023-Q3 | — | $6.3M | $26M+ $63M short-term inv. | $7.7M-$7.3M operating cash flow | report ↗ |
| 2023-Q2 | — | $5.8M | $14M+ $80M short-term inv. | $7.2M-$9.9M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.0M | $12M+ $100M short-term inv. | $6.4M-$8.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.8M | $67M+ $59M short-term inv. | $8.3M-$8.6M operating cash flow | report ↗ |
| 2022-Q2 | — | $5.1M | $25M+ $53M short-term inv. | $8.1M-$6.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $4.6M | $29M | $7.3M-$7.1M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.7M | $29M | $7.3M-$7.2M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $33M | $19M+ $169M short-term inv. | $11M-$42M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $39M | $34M+ $74M short-term inv. | $12M-$38M operating cash flow | report ↗ |
| 2023-FY | — | $24M | $32M+ $51M short-term inv. | $7.3M-$32M operating cash flow | report ↗ |
| 2022-FY | — | $20M | $13M+ $108M short-term inv. | $7.3M-$28M operating cash flow | report ↗ |
| 2021-FY | — | $23M | $37M | $8.5M-$29M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($596K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-15 | Heffernan Michael Thomas · director | Option exercise | 18,421 | $3.04 | $56K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Open-market sale | 18,321 | $15.09 | $276K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Open-market sale | 100 | $15.88 | $2K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Option exercise | 21,052 | $3.33 | $70K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Open-market sale | 20,952 | $15.09 | $316K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Open-market sale | 100 | $15.88 | $2K | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Option exercise (derivative) | 18,421 | — | — | Form 4 |
| 2026-09-15 | Heffernan Michael Thomas · director | Option exercise (derivative) | 21,052 | — | — | Form 4 |